American Society of Clinical Oncology (ASCO) Annual Meeting 2023

by EpicentRx | Sep 1, 2023 | Conferences

June 2023; Chicago, Illinois Poster: RRX-001 Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001 TGF-ß Trap (NCT04673942) Poster: RRX-001, KEVLARx: A phase 2b, multi-institutional, randomized,...

A View to a Kill: Are viruses alive or dead and is it time to find out?

by EpicentRx | Sep 1, 2023 | Media

Therapeutic frontiers: the potential of RRx-001 and AdAPT-001

by EpicentRx | Aug 25, 2023 | Media

Molecule RRx-001 Receives Fast Track Designation From the FDA – EpicentRx

by EpicentRx | Aug 3, 2023 | Media

AdAPT-001 oncolytic adenovirus shows promising phase 1 cancer treatment results

by EpicentRx | Jun 8, 2023 | Media